BioStratum

About BioStratum

BioStratum, Inc., founded in 1998 by Karl Tryggvason, operated as a biopharmaceutical company headquartered in Durham, North Carolina. The firm concentrated on developing therapeutic agents for degenerative and invasive diseases, with a particular focus on conditions like diabetes, cancer, and kidney disease. The company's strategy revolved around targeting the basal lamina, a specialized component of the extracellular matrix that plays a crucial role in the pathological changes associated with these diseases. BioStratum's business model appears to have been centered on drug development, aiming to advance its product candidates through clinical trials to eventually secure partnerships or market approval.

The company's most advanced product candidate was Pyridorin (pyridoxamine), which was designed to inhibit the formation of advanced glycation end-products (AGEs), a significant factor in the development of diabetic kidney disease. In early 2000, BioStratum successfully closed on $28 million in private financing to advance Pyridorin through Phase II clinical trials. Another key asset in its pipeline was Angiocol, an anti-angiogenesis drug intended as an adjunctive therapy for malignant melanoma by restricting the blood supply to tumors. The company also developed a diagnostic test, gamma 2-Metastain, for detecting metastatic cancer and was exploring the use of its proprietary recombinant laminins for wound repair and tissue regeneration. Operations were supported by a research subsidiary, BioStratum AB, located in Stockholm. According to company profiles, BioStratum is now considered a deadpooled company.